Fig 1.
The study arms and follow-up process in the study.
Table 1.
Demographic and clinical characteristics of volunteers in the homologous and heterologous ChAdOx1-S and BBIBP-CorV vaccine groups.
Fig 2.
Scatter plot of anti-Spike IgG antibody responses before and four weeks after the booster dose in four study groups.
A) General; B) antibody status in individuals without COVID-19 infection history; and C) antibody status in individuals without COVID-19 infection history. Geometric mean titer on log 10 scale and 95% confidence intervals are shown. Within-group differences (before and after the booster injection) are estimated using the Wilcoxon match pair test. Differences in antibody titer after the booster injection between homologues and heterologous groups are estimated using Mann-Whitney U test. Significant differences are indicated within the figures; *** indicates P values that are significant at <0.0001 levels, ** indicates P values less than 0.01, and * indicates P values less than 0.05 levels.
Fig 3.
Scatter plot of neutralizing antibody responses before and four weeks after the booster dose in four study groups. A) General; B) antibody status in individuals without COVID-19 infection history; and C) antibody status in individuals without COVID-19 infection history.
Geometric mean titer on log 10 scale and 95% confidence intervals are shown. Within-group differences (before and after the booster injection) are estimated using the Wilcoxon match pair test. Differences in antibody titer after the booster injection between homologues and heterologous groups are estimated using Mann-Whitney U test. Significant differences are indicated within the figures; *** indicates P values that are significant at <0.0001 levels, ** indicates P values less than 0.01, and * indicates P values less than 0.05 levels.
Table 2.
Anti-Spike IgG geometric mean titer (GMT), mean rise, fold rise, and fourfold rise rate between ChAdOx1-S and BBIBP-CorV homologous and heterologous groups.
Table 3.
Neutralizing antibody geometric mean titer (GMT), mean rise, fold rise, and fourfold rise rate between ChAdOx1-S and BBIBP-CorV homologous and heterologous groups.
Table 4.
Crude and adjusted effect of homologous vs. heterologous boosters on anti-Spike IgG and neutralizing Ab fourfold rise in primed recipients with ChAdOx1-S and BBIBP CorV.
Fig 4.
Comparison of virus neutralizing test between the applied boosters.
Sera from vaccinated individuals with complete schedule were evaluated (cVNT50: GMT, 95% CI) against Omicron BA.5 variant. Ns indicates no significant between heterologous or homologous ChAdOx1-S (P: 0.42) nor heterologous/homologous BBIP-CorV (P: 0.08).